From chemotherapy to targeted precision: A paradigm shift in the frontline treatment of Ph+ ALL - A dialogue between Robin Foà, Filippo Milano and Sabina Chiaretti

In this episode, Prof. Robin Foà, Prof. Filippo Milano and Prof. Sabina Chiaretti explore the first results of a worldwide randomized phase 3 trial that challenges a long-standing paradigm in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL): the necessity of frontline chemotherapy. The discussion focuses on a direct comparison between a fully chemo-free strategy—combining Ponatinib and Blinatumomab—and the conventional standard of care based on Imatinib plus chemotherapy.The trial enrolled 236 patients with no upper age limit and introduced age-adapted dosing of Ponatinib alongside strictly biology-driven criteria for allogeneic transplantation, based on molecular response, ABL1 mutations, and the Ikaros-plus genotype. Intensified central nervous system prophylaxis addressed the historically high risk of CNS relapse in this disease.The speakers highlight the superiority of the chemo-free arm, which achieved higher hematological and molecular remission rates, improved event-free survival, and a marked reduction in the need for transplantation. These benefits were accompanied by better tolerability, with fewer severe adverse events and no excess cardiovascular toxicity compared with chemotherapy.Looking ahead, the episode reflects on the broader clinical implications of these findings, particularly for elderly patients and those unfit for intensive therapy. The discussion also opens the door to the possibility of long-term treatment-free remission in patients achieving deep and durable molecular responses, while acknowledging ongoing challenges in global access to advanced diagnostics and targeted therapies.A concise yet in-depth conversation on how precision medicine is reshaping the future of Ph+ ALL—moving the field closer to effective, chemotherapy-free frontline care.